co-administration of cefepime and nacubactam

DRUG2 trials

Sponsors

Meiji Seika Pharma Co., Ltd.

Conditions

APAcute PyelonephritisComplicated Intra-abdominal InfectionComplicated Urinary Tract InfectionHospital-acquired Bacterial PneumoniaVentilator-associated Bacterial PneumoniacUTI

Phase 3

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

CompletedNCT05887908

Meiji Seika Pharma Co., Ltd.Acute Pyelonephritis, AP, Complicated Urinary Tract Infection +1

Start: 2023-05-23End: 2024-11-26Updated: 2025-12-24

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

CompletedNCT05905055

Meiji Seika Pharma Co., Ltd.Acute Pyelonephritis, Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection +2

Start: 2023-09-22End: 2025-09-01Updated: 2026-03-19